Evidence map›Paper›PMID 23021687›Full record

SynthesisAmerican journal of obstetrics and gynecology2012

Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis.

Ioannis D Gallos, Jason Yap, Madhurima Rajkhowa, David M Luesley, Arri Coomarasamy, Janesh K Gupta

2 registry-linked trialsOpen access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in American journal of obstetrics and gynecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 146 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 7 pooled it
15.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07462663 phase4not yet recruitingstarted 2027, after this paper: background citation

SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg/m²

Ran2027Enrolled80Registered outcomes34Posted comparisons0ConditionsAtypical Endometrial Hyperplasia, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, BMI>40, Endometrial CancerArmsDietetic-Nutritional intervention, Endometrial Biopsy With or Without Hysteroscopy, GLP-1 receptor agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins
PMID 33755728PMID 33667417PMID 36216945PMID 29266019PMID 17096437PMID 25791635PMID 27654262PMID 27901412PMID 30193337PMID 33397713PMID 34238643PMID 35314087other papers from this trial
Open the trial in the graph
NCT03538704 naunknown statusnot on this mapstarted 2015, after this paper: background citation

Effect of Fertility-sparing Therapy of Early Endometrial Cancer

TypeinterventionalSponsorPeking University People's HospitalRan2015 to 2020Enrolled80ConditionsEndometrial Cancer, FertilityArmsMetformin
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 7 syntheses or guidelines pooled it, 369 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Endometrial hyperplasia as a risk factor of endometrial cancer.Archives of gynecology and obstetrics · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Updates and evolving care paradigms for pre-menopausal patients with endometrial cancer.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
    Review

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ioannis D GallosAcademic Unit of Obstetrics and Gynaecology, Birmingham Women's Hospital, Birmingham, England, United Kingdom. ioannis.gallos@nhs.net
Jason Yap
Madhurima Rajkhowa
David M Luesley
Arri Coomarasamy
Janesh K Gupta
Birmingham Women's Hospital · GBBirmingham City Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of the study was to evaluate the regression, relapse, and live birth rates of early-stage endometrial cancer (EC) and atypical complex hyperplasia (ACH) with fertility-sparing treatment. STUDY

designThis was a metaanalysis of the proportions from observational studies with a random-effects model and a meta-regression to explore for heterogeneity.

resultsThirty-four observational studies, evaluating the regression, relapse, and live birth rates of early-stage EC (408 women) and ACH (151 women) with fertility-sparing treatment. Fertility-sparing treatment for EC achieved a pooled regression rate of 76.2%, a relapse rate of 40.6%, and a live birth rate of 28%. For ACH the pooled regression rate was 85.6%, a relapse rate of 26%, and a live birth rate of 26.3%. Twenty women were diagnosed with ovarian cancer (concurrent or metastatic) during follow-up (3.6%) and 10 progressed to higher than stage I EC (1.9%) from which 2 women died.

conclusionFertility-sparing treatment of EC and ACH is feasible and selected women can satisfy their reproductive wishes.

Indexed as

FertilityAdenocarcinomaAdultBirth RateEndometrial HyperplasiaEndometrial NeoplasmsFemaleHumansPregnancyPregnancy Complications, NeoplasticTreatment Outcome

Identifiers

PMID23021687
OpenAlexW2063680792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.